M&A / Deals MSD-backed Ray locks in $125m to back eye drug pipeline Pharmaceutical TechnologyRay's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.M&A / DealsOphthalmologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline. M&A / DealsOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New data build case for Roche’s oral BTK drug for MSNext: FDA delays decision on Sanofi’s subcutaneous Sarclisa Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
